ICYMI: AstraZeneca Profit, Revenue Lifted by ...

Intel gave a strong sales forecast for the current period, signaling that the struggling chipmaker is finally beginning to benefit from the giant build-out of artificial intelligence infrastructure.Revenue will be $13.8 billion to $14.8 billion in the quarter ending in June, the ...  Show more

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. The US Justice Department reclassified state-regulated marijuana as a less dangerous drug, a major shift that could increase legal cannabis sales and ...  Show more

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...

David Faber and Jim Cramer discuss the massive surge for stocks. Multiple reports emerging saying dexamethasone, a widely available drug, can help critically ill coronavirus patients. The treatment reportedly reduced Covid-19 deaths in hospitalized patients by up to one third. ...

David Faber and Jim Cramer began the hour by breaking down another volatile day for the markets, with the major indices coming off their 4th negative session in 5. JPMorgan also raised their odds of a U.S. recession by year end to 35%. A big earnings mover today included Eli L ...

Carl Quintanilla and Jim Cramer focused on shares of Intel tumbling after the chipmaker posted fourth-quarter results that missed expectations -- and warned of a loss in Q1. The anchors reacted to CEO Pat Gelsinger's earnings call comment: "We realize that we stumbled." The Fed's ...  Show more